MAPT and Alzheimer disease: Importantly, Armanezumab recognized pathological tau in cortices not only from AD cases but also from Frontotemporal Dementia and Pick’s Disease, similarly to other antibodies specific to pathological or total tau, such as PHF1, AT8, AT100, HT7 and TNT-1.